Influence of substitution of brand name for generic drugs on therapeutic compliance in hypertension and dyslipidemia;Influencia de la sustitución de medicamentos de marca por genéricos en el cumplimiento terapéutico de la hipertensión arterial y la dislipidemia

Gaceta Sanitaria

Volumn 24, Issue 6, 2010, Pages 473-482

  Sicras Mainar, Antoni ^a   Navarro Artieda, Ruth ^b  

^a Badalona Serveis Assistencials SA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Adherence; Compliance; Dyslipidemia; Generic drugs; Generic substitution; Hypertension

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; GENERIC DRUG; SIMVASTATIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG SUBSTITUTION; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; MULTICENTER STUDY; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; STATISTICS;

ADULT; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; DRUG SUBSTITUTION; DRUGS, GENERIC; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTENSION; HYPOLIPIDEMIC AGENTS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; SIMVASTATIN;

EID: 78649636450     PISSN: 02139111     EISSN: 15781283     Source Type: Journal    
DOI: 10.1016/j.gaceta.2010.07.007     Document Type: Article

References (41)

1. Darbà J. Pharmaceutical expenditure in Spain: evolution and cost containment measures during 1998-2001. Eur J Health Econ 2003, 4:151-157.
2. Puig-Junoy J. The financing and price regulation of drugs in the Spanish National Health System: changes and continuity. Gac Sanit 2007, 21:1-4.
3. Borrell JR, Merino-Castelló A. Perverse effects of pharmaceutical regulation in Spain. How much will it affect price competition?. Gac Sanit 2006, 20(Suppl 2):41-50.
4. Cobedo V, Poveda JL, Peiró S, et al. Factores determinantes del gasto por prescripción farmacéutica en atención primaria. Aten Primaria 1995, 16:407-416.
5. Antoñanzas Villar F. El consumo de medicamentos: políticas y pacto social. Gac Sanit 2000, 14:93-96.
6. Coma A, Zara C, Godman B, et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction. Expert Rev Pharmacoecon Outcomes Res 2009, 9:569-581.
7. Granda E. Prescripción de genéricos o por principio activo. Cuestión de conveniencia. Farmacia Profesional 2007, 21:8-13.
8. Ley 13/1996 de 30 de Diciembre, de Medidas Fiscales, Administrativas y del Orden Social. Artículo 169. Modificación de la ley 25/1990, de 20 de Diciembre.
9. Puig-Junoy J. Los medicamentos genéricos pagan el precio de ser referencia. Rev Adm Sanit 2004, 2:35-59.
10. Palma Morgado D, Domínguez Camacho JC. Generic drugs, a matter of bioequivalence. Farm Hosp 2007, 31:73-74.
11. Ruiz-Rico T, Moreno Villar A, Nacle López I. Algunas reflexiones sobre los medicamentos genéricos. Farm Hosp 2008, 32:182-183.
12. Honrubia Alujer F, Carbajal de Lara JA, Cebrián Picazo C, et al. Grupo de Investigación del COF Albacete. Acceptance of replacement by generic medicines at community pharmacies. Aten Primaria 2007, 39:81-85.
13. Sagardui-Villamor JK, Lacalle Rodríguez-Labajo M, Casado-Buendía S. Sustitución de medicamentos de marca por genéricos en atención primaria. Factores asociados al rechazo. Aten Primaria 2005, 36:489-493.
14. García AJ, Martos F, Leiva F, et al. Genéricos: ¿buenos o malos? Conocimientos y actitudes de los médicos ante los medicamentos genéricos. Gac Sanit 2003, 17:144-149.
15. Blasco Oliete M, Torres Bouza C, Medina Bustillo B, et al. Opinión de los usuarios de atención primaria sobre los medicamentos genéricos y el coste de la medicación. Aten Primaria 2003, 31:170-177.
16. Shrank WH, Cadarette SM, Cox E, et al. Is there a relationship between patient beliefs or communication about generic drugs and medication utilization?. Med Care 2009, 47:319-325.
17. Kjoenniksen I, Lindbaek M, Granas AG. Patients' attitudes towards and experiences of generic drug substitution in Norway. Pharm World Sci 2006, 28:284-289.
18. Federman AD, Halm EA, Zhu C, et al. Association of income and prescription drug coverage with generic medication use among older adults with hypertension. Am J Manag Care 2006, 12:611-618.
19. Vallès JA, Barreiro M, Cereza G, et al. Aceptación de los fármacos genéricos en equipos de atención primaria: efecto de una intervención educativa y de los precios de referencia. Gac Sanit 2002, 16:505-510.
20. Guidelines for the management of arterial hypertension The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25:1105-1187.
21. Elliott WJ. Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy. J Clin Hypertens (Greenwich) 2009, 11:376-382.
22. Ricarte Díez JI, Benounna H, Velarde Mayol C, et al. Diferencias entre prescripción y dispensación de genéricos en atención primaria. La excepción como regla. Gac Sanit 2007, 21:404-406.
23. Canadillas-Hidalgo FM, Sánchez-Álvarez JC, Serrano-Castro PJ, et al. en representacion de la Sociedad Andaluza de Epilepsia. Consensus clinical practice guidelines of the Andalusian Epilepsy Society on prescribing generic antiepileptic drugs. Rev Neurol 2009, 49:41-47.
24. Meredith PA. Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms. Curr Med Res Opin 2009, 25:2179-2189.
25. Håkonsen H, Eilertsen M, Borge H, et al. Generic substitution: additional challenge for adherence in hypertensive patients?. Curr Med Res Opin 2009, 25:2515-2521.
26. Van Wijk BL, Klungel OH, Heerdink ER, et al. Generic substitution of antihypertensive drugs: does it affect adherence?. Ann Pharmacother 2006, 40:15-20.
27. Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008, 300:2514-2526.
28. The International Classification of Primary Care in the European Community. With a multi-language layer 1993, Oxford University Press, Oxford. H. Lamberts, M. Wood, I.M. Hofmans-Okkes (Eds.).
29. National Cholesterol Education Program - Expert Panel on Detection Evaluation, and Treatment on High Blood Cholesterol in Adults (Adult Treatment Panel iii). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Adult Treatment Panel iii final report. Circulation 2002, 106:3143-3421.
30. Anónimo Guidelines for ATC classification 1991, Nordic Collaborating Centre for Drug Statistics Methodology, Oslo.
31. Rigueira García A. Treatment compliance: what do we know about Spain?. Aten Primaria 2001, 27:559-568.
32. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
33. Weiner JP, Starfield BH, Steinwachs DM, et al. Development and application of a population-oriented measure of ambulatory care case-mix. Med Care 1991, 29:452-472.
34. Sackett D, Rosenberg W, Gray J, et al. Evidence based medicine: what it is and what it isn't. BMJ 1996, 312:71-72.
35. Gerth WC. Compliance and persistence with newer antihypertensive agents. Curr Hypertens Rep 2002, 4:424-433.
36. Bramley TJ, Gerbino PP, Nightengale BS, et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006, 12:239-245.
37. Shrank WH, Hoang T, Ettner SL, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med 2006, 166:332-337.
38. Ganther JM, Kreling DH. Consumer perceptions of risk and required cost savings for generic prescription drugs. J Am Pharmaceutical Assoc 2000, 40:378-383.
39. Pitt B. Generic drugs in cardiology: hill they reduce health care costs?. JACC 2004, 44:10-13.
40. Federman AD, Halm EA, Siu AL. Use of generic cardiovascular medicactions by elderly medicare beneficiaries receiving generalist of cardiologist care. Med Care 2007, 45:109-115.
41. Córdoba García R. Especialidades farmacéuticas frente a genéricos. Hipertensión 2008, 25:169-174.